**GB00BMVP7Y09 - Common Stock **

We assign a fundamental rating of **5** out of 10 to **RPRX**. **RPRX** was compared to 257 industry peers in the **Pharmaceuticals** industry. **RPRX** has a medium financial health rating, its profitability is only medium as well. **RPRX** has a correct valuation and a medium growth rate.

ROA (2.87%) VS Industry: 87% outperformed.

-1,292.14

111.39

ROE (8.24%) VS Industry: 29% outperformed.

1.38

176.97

Profit Margin (22.55%) VS Industry: 92% outperformed.

-53,337.68

1,968.82

The **Forward Price/Earnings Ratio** of **11.91** indicates a rather cheap valuation of **RPRX**.

The **Price/Earnings Ratio** is **14.52**, which indicates a correct valuation of **RPRX**.

With a price book ratio of **3.03**, **RPRX** is valued correctly.

When comparing the price book ratio of **RPRX** to the average industry price book ratio of 1.43, **RPRX** is valued more expensive than its industry peers.

Price/Earnings (14.52) VS Industry: 44% outperformed.

85.27

0.75

Price/Book (3.03) VS Industry: 29% outperformed.

302.05

0.09

Based on estimates for the next 5 years, **RPRX** will show a quite strong growth in **Earnings Per Share**. The EPS will grow by **18.15%** on average per year.

When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.

Looking at the last year, **RPRX** shows a decrease in **Revenue**. The Revenue has decreased by **-1.69%** in the last year.

Measured over the past 5 years, **RPRX** shows a small growth in **Revenue**. The Revenue has been growing by **8.45%** on average per year.

Based on estimates for the next 5 years, **RPRX** will show a small growth in **Revenue**. The Revenue will grow by **6.87%** on average per year.

The Revenue growth is stable: in the next 5 years the growth will be about the same than in the last 5 years.

Past | Future | ||||||
---|---|---|---|---|---|---|---|

5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |

EPS | N/A | -13.57% | 70.18% | 37.55% | 26.12% | 21.58% | 18.15% |

Revenue | N/A | 8.45% | -1.69% | 8.62% | 7.42% | 9.6% | 6.87% |

A Current Ratio of **2.07** indicates that **RPRX** has no problem at all paying its short term obligations.

A Quick Ratio of **2.07** indicates that **RPRX** has no problem at all paying its short term obligations.

The Altman-Z score of **RPRX** is much better than the industry average of **-0.53**.

Compared to an average industry Current Ratio of 3.51, **RPRX** is worse placed to pay its short term obligations than its industry peers.

Compared to an average industry Quick Ratio of 2.88, **RPRX** is worse placed to pay its short term obligations than its industry peers.

Debt/Equity (0.99) VS Industry: 12% outperformed.

59.36

0.00

Quick Ratio (2.07) VS Industry: 37% outperformed.

-2.73

76.82

Current Ratio (2.07) VS Industry: 28% outperformed.

0.09

76.82

Altman-Z (1.59) VS Industry: 66% outperformed.

-231.44

114.17

With a **Yearly Dividend Yield** of **1.77%**, **RPRX** has a reasonable but not impressive dividend return.

Dividend Yield (1.77%) VS Industry: 22% outperformed.

0.67

7.18

NASDAQ:RPRX (12/7/2022, 12:41:06 PM)**+0.31 (+0.74%) **

GICS Sector | Health Care | ||

GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||

GICS Industry | Pharmaceuticals | ||

Earnings (Last) | 11-08 2022-11-08/bmo | Earnings (Next) | 02-13 2023-02-13 |

Ins Owners | 0.1% | Inst Owners | 67.07% |

Market Cap | 18.63B | Analysts | 81.11 |

PE | 14.52 | Fwd PE | 11.91 |

PEG (NY) | 0.39 | PEG (5Y) | N/A |

P/S | 8.29 | P/B | 3.03 |

EV/EBITDA | N/A |

Dividend Yield | 1.77% | Dividend Growth | N/A |

DP | 63.68% | Ex-Date | 11-17 2022-11-17 (0.19) |

EPS 1Y | 70.18% | EPS 3Y | -13.57% |

EPS 5Y | N/A | EPS growth Q2Q | 323.53% |

EPS Next Y | 37.55% | EPS Next 2Y | 26.12% |

EPS Next 3Y | 21.58% | EPS Next 5Y | 18.15% |

Revenue growth 1Y | -1.69% | Revenue growth 3Y | 8.45% |

Revenue growth 5Y | N/A | Revenue growth Q2Q | -2.1% |

Revenue Next Year | 8.62% | Revenue Next 2Y | 7.42% |

Revenue Next 3Y | 9.6% | Revenue Next 5Y | 6.87% |

Current Ratio | 2.07 | Quick Ratio | 2.07 |

Altman-Z | 1.59 | F-Score | 4 |

Debt/Equity | 0.99 | WACC | 8.26% |

ROIC/WACC | 0.63 |

ROA | 2.87% | ROE | 8.24% |

ROICexgc | 5.2% | ROIC | 4.5% |

PM | 22.55% | OM | 41.97% |

Asset Turnover | 0.13 |

*Find stocks with similar Fundamental rating on the USA*

*Find the competitors with the best fundamentals on the USA*

*Find the competitors with the best valuation on the USA*

*Find the competitors with the best dividend on the USA*